Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2015 (2015), Article ID 876752, 4 pages
http://dx.doi.org/10.1155/2015/876752
Case Report

Rare Form of Erdheim-Chester Disease Presenting with Isolated Central Skeletal Lesions Treated with a Combination of Alfa-Interferon and Zoledronic Acid

1First Pavlov State Medical University of St. Petersburg, L’va Tolstogo Street, No. 6/8, Saint Petersburg 197022, Russia
2University Hospital Carl Gustav Carus, Fetscherstrasse 74, 01307 Dresden, Germany

Received 19 December 2014; Revised 18 March 2015; Accepted 19 March 2015

Academic Editor: Ramon Tiu

Copyright © 2015 E. N. Bulycheva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. R. Klieger, E. Schultz, D. E. Elkowitz, M. Arlen, and S. I. Hajdu, “Erdheim-Chester disease: a unique presentation with multiple osteolytic lesions of the spine and pelvis that spared the appendicular skeleton,” The American Journal of Roentgenology, vol. 178, no. 2, pp. 429–432, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. E. L. Diamond, L. Dagna, D. M. Hyman et al., “Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease,” Blood, vol. 124, no. 4, pp. 483–492, 2014. View at Publisher · View at Google Scholar
  3. J. Haroche, F. Charlotte, L. Arnaud et al., “High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses,” Blood, vol. 120, no. 13, pp. 2700–2703, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. J.-F. Emile, F. Charlotte, Z. Amoura, and J. Haroche, “BRAF mutations in erdheim-chester disease,” Journal of Clinical Oncology, vol. 31, article 398, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. V. V. Krishna, T. E. James, K. T. Chang, and S. S. Yen, “Erdheim-Chester disease with rare radiological features in a 14-year old girl with pre-B acute lymphocytic leukemia and diabetes mellitus,” Journal of Radiology Case Reports, vol. 8, no. 8, pp. 7–15, 2014. View at Publisher · View at Google Scholar
  6. J. Haroche, F. Cohen-Aubart, J. F. Emile et al., “Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAFV600E-mutated Erdheim-Chester disease,” Journal of Clinical Oncology, vol. 33, no. 5, pp. 411–418, 2015. View at Publisher · View at Google Scholar
  7. T. Luft, K. C. Pang, and E. Thomas, “Type I interferons enhance the terminal differentiation of dendritic cells,” The Journal of Immunology, vol. 161, pp. 1947–1953, 1998. View at Google Scholar
  8. F. Braiteh, C. Boxrud, B. Esmaeli, and R. Kurzrock, “Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alfa,” Blood, vol. 106, no. 9, pp. 2992–2994, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Haroche, Z. Amoura, S. G. Trad et al., “Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients,” Arthritis and Rheumatism, vol. 54, no. 10, pp. 3330–3336, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. H. I. Suzuki, N. Hosoya, K. Miyagawa et al., “Erdheim-Chester disease: multisystem involvement and management with interferon-α,” Leukemia Research, vol. 34, no. 1, pp. e21–e24, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Arnaud, B. Hervier, A. Néel et al., “CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients,” Blood, vol. 117, no. 10, pp. 2778–2782, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Mossetti, D. Rendina, F. G. Numis, P. Somma, L. Postiglione, and V. Nunziata, “Biochemical markers of bone turnover, serum levels of interleukin-6/interleukin-6 soluble receptor and bisphosphonate treatment in Erdheim-Chester disease,” Clinical and Experimental Rheumatology, vol. 21, no. 2, pp. 232–236, 2003. View at Google Scholar · View at Scopus
  13. S. Eyigör, Y. Kirazli, A. Memis, and G. Başdemir, “Erdheim-Chester disease: the effect of bisphosphonate treatment—a case report,” Archives of Physical Medicine and Rehabilitation, vol. 86, no. 5, pp. 1053–1057, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Srikulmontree, H. D. Massey, and W. N. Roberts, “Treatment of skeletal Erdheim-Chester disease with zoledronic acid: case report and proposed mechanisms of action,” Rheumatology International, vol. 27, no. 3, pp. 303–307, 2007. View at Publisher · View at Google Scholar · View at Scopus